Selective ROCK2 inhibition in focal cerebral ischemia

Annals of Clinical and Translational Neurology

Volumn 1, Issue 1, 2014, Pages 2-14

  Hyun Lee, Jeong ^a,e   Zheng, Yi ^a   von Bornstadt, Daniel ^a   Wei, Ying ^a   Balcioglu, Aygul ^a   Daneshmand, Ali ^a   Yalcin, Nilufer ^a   Yu, Esther ^a   Herisson, Fanny ^a   Atalay, Yahya B ^a   Kim, Maya H ^a   Ahn, Yong Joo ^a   Balkaya, Mustafa ^a   Sweetnam, Paul ^b   Schueller, Olivier ^b   Poyurovsky, Masha V ^c   Kim, Hyung Hwan ^a   Lo, Eng H ^a   Furie, Karen L ^d   Ayata, Cenk ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Surface Logix Inc   (United States)

^c Kadmon Research Institute   (United States)

^d RHODE ISLAND HOSPITAL   (United States)

^e Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; KD 025; RHO ASSOCIATED KINASE 2; RHO KINASE; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE RATIO; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; MALE; MASS SPECTROMETRY; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC ASSAY; PRIORITY JOURNAL; SINGLE DRUG DOSE; TISSUE PERFUSION; WESTERN BLOTTING;

EID: 84978266250     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.19     Document Type: Article

References (48)

1. Shin HK, Salomone S, Ayata C. Targeting cerebrovascular Rho-kinase in stroke. Expert Opin Ther Targets 2008;12:1547-1564.
2. Iizuka M, Kimura K, Wang S, et al. Distinct distribution and localization of Rho-kinase in mouse epithelial, muscle and neural tissues. Cell Struct Funct 2012;37:155-175.
3. Nakagawa O, Fujisawa K, Ishizaki T, et al. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 1996;392:189-193.
4. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003;4:446-456.
5. Shin HK, Salomone S, Potts EM, et al. Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms. J Cereb Blood Flow Metab 2007;27:998-1009.
6. Klages B, Brandt U, Simon MI, et al. Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol 1999;144:745-754.
7. Wang QM, Liao JK. ROCKs as immunomodulators of stroke. Expert Opin Ther Targets 2012;16:1013-1025.
8. Kahles T, Luedike P, Endres M, et al. NADPH oxidase plays a central role in blood-brain barrier damage in experimental stroke. Stroke 2007;38:3000-3006.
9. Wu J, Li J, Hu H, et al. Rho-kinase inhibitor, fasudil, prevents neuronal apoptosis via the Akt activation and PTEN inactivation in the ischemic penumbra of rat brain. Cell Mol Neurobiol 2012;32:1187-1197.
10. Lau CL, Perreau VM, Chen MJ, et al. Transcriptomic profiling of astrocytes treated with the Rho kinase inhibitor fasudil reveals cytoskeletal and pro-survival responses. J Cell Physiol 2012;227:1199-1211.
11. Lord-Fontaine S, Yang F, Diep Q, et al. Local inhibition of Rho signaling by cell-permeable recombinant protein BA-210 prevents secondary damage and promotes functional recovery following acute spinal cord injury. J Neurotrauma 2008;25:1309-1322.
12. Dergham P, Ellezam B, Essagian C, et al. Rho signaling pathway targeted to promote spinal cord repair. J Neurosci 2002;22:6570-6577.
13. Ishiguro M, Kawasaki K, Suzuki Y, et al. A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator. Neuroscience 2012;220:302-312.
14. Koumura A, Hamanaka J, Kawasaki K, et al. Fasudil and ozagrel in combination show neuroprotective effects on cerebral infarction after murine middle cerebral artery occlusion. J Pharmacol Exp Ther 2011;338:337-344.
15. Satoh S, Toshima Y, Hitomi A, et al. Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model. Brain Res 2008;1193:102-108.
16. Boerma M, Fu Q, Wang J, et al. Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin. Blood Coagul Fibrinolysis 2008;19:709-718.
17. Fisher M, Feuerstein G, Howells DW, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009;40:2244-2250.
18. Fisher M. Recommendations for advancing development of acute stroke therapies: Stroke Therapy Academic Industry Roundtable 3. Stroke 2003;34:1539-1546.
19. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30:2752-2758.
20. Kilkenny C, Browne WJ, Cuthill IC, et al. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 2010;8:e1000412.
21. Asahi M, Huang Z, Thomas S, et al. Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J Cereb Blood Flow Metab 2005;25:722-729.
22. Zhang Y, Huo M, Zhou J, Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 2010;99:306-314.
23. Lin TS, Neenan JP, Cheng YC, Prusoff WH. Synthesis and antiviral activity of 5- and 5'-substituted thymidine analogs. J Med Chem 1976;19:495-498.
24. Eikermann-Haerter K, Hyun Lee J, Yuzawa I, et al. Migraine mutations increase stroke vulnerability by facilitating ischemic depolarizations. Circulation 2012;125:335-345.
25. Balkaya M, Krober J, Gertz K, et al. Characterization of long-term functional outcome in a murine model of mild brain ischemia. J Neurosci Methods 2013;213:179-187.
26. Freret T, Bouet V, Leconte C, et al. Behavioral deficits after distal focal cerebral ischemia in mice: usefulness of adhesive removal test. Behav Neurosci 2009;123:224-230.
27. Shin HK, Dunn AK, Jones PB, et al. Vasoconstrictive neurovascular coupling during focal ischemic depolarizations. J Cereb Blood Flow Metab 2006;26:1018-1030.
28. Rikitake Y, Kim HH, Huang Z, et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005;36:2251-2257.
29. Duffy P, Schmandke A, Schmandke A, et al. Rho-associated kinase II (ROCKII) limits axonal growth after trauma within the adult mouse spinal cord. J Neurosci 2009;29:15266-15276.
30. Hashimoto R, Nakamura Y, Kosako H, et al. Distribution of Rho-kinase in the bovine brain. Biochem Biophys Res Commun 1999;263:575-579.
31. Ishizaki T, Maekawa M, Fujisawa K, et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 1996;15:1885-1893.
32. Leung T, Chen XQ, Manser E, Lim L. The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol 1996;16:5313-5327.
33. Miyagi Y, Carpenter RC, Meguro T, et al. Upregulation of rho A and rho kinase messenger RNAs in the basilar artery of a rat model of subarachnoid hemorrhage. J Neurosurg 2000;93:471-476.
34. Wei L, Roberts, W, Wang L, et al. Rho kinases play an obligatory role in vertebrate embryonic organogenesis. Development 2001;128:2953-2962.
35. Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 1996;15:2208-2216.
36. Noma K, Rikitake Y, Oyama N, et al. ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest 2008;118:1632-1644.
37. Zhang YM, Bo J, Taffet GE, et al. Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis. Faseb J 2006;20:916-925.
38. Rikitake Y, Oyama N, Wang CY, et al. Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/- haploinsufficient mice. Circulation 2005;112:2959-2965.
39. Schueller O, Tong W, Ferkany J, Sweetnam P. Selective ROCK 2 inhibition attenuates arterial plaque formation in an ApoE knockout mouse model. Circulation 2006;114:II-228.
40. Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 2006;290:C661-C668.
41. Breyer J, Samarin J, Rehm M, et al. Inhibition of Rho kinases increases directional motility of microvascular endothelial cells. Biochem Pharmacol 2012;83:616-626.
42. Ding J, Li QY, Wang X, et al. Fasudil protects hippocampal neurons against hypoxia-reoxygenation injury by suppressing microglial inflammatory responses in mice. J Neurochem 2010;114:1619-1629.
43. Satoh S, Kobayashi T, Hitomi A, et al. Inhibition of neutrophil migration by a protein kinase inhibitor for the treatment of ischemic brain infarction. Jpn J Pharmacol 1999;80:41-48.
44. Satoh S, Utsunomiya T, Tsurui K, et al. Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage. Life Sci 2001;69:1441-1453.
45. Yang SA, Carpenter CL, Abrams CS. Rho and Rho-kinase mediate thrombin-induced phosphatidylinositol 4-phosphate 5-kinase trafficking in platelets. J Biol Chem 2004;279:42331-42336.
46. Ono A, Westein E, Hsiao S, et al. Identification of a fibrin-independent platelet contractile mechanism regulating primary hemostasis and thrombus growth. Blood 2008;112:90-99.
47. Kast R, Schirok H, Figueroa-Perez S, et al. Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase. Br J Pharmacol 2007;152:1070-1080.
48. Saver JL, Kidwell C, Eckstein M, et al. Prehospital neuroprotective therapy for acute stroke: results of the field administration of stroke therapy-magnesium (FAST-MAG) pilot trial. Stroke 2004;35:e106-e108.